Copyright Seeking Alpha
McKesson raises 2026 EPS guidance to $38.35–$38.85 while advancing oncology and specialty platforms Nov. 05, 2025 7:22 PM ETMcKesson Corporation (MCK) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: McKesson Corporation (MCK) Q2 2026 Management View Brian Tyler, CEO, reported "strong second quarter results, which reflect sustained momentum in our business and the strength of our diversified portfolio." He highlighted consolidated revenues for the quarter of $103 billion, a 10% year-over-year increase, and adjusted earnings Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights McKesson raised its fiscal 2026 adjusted EPS guidance and expects strong revenue and operating profit growth across all core segments. Oncology and Multispecialty, Prescription Technology Solutions, and North American Pharmaceutical are leading revenue and profit growth, boosted by acquisitions and product demand. McKesson is updating its reporting structure, investing in automation and technology, executing acquisitions, and planning to separate the Medical-Surgical Solutions business via IPO. Recommended For You More Trending News
